Photo Credit: andresr

The following is a summary of “Patient Outcomes and Safety of Combination Biologic Therapy with Dupilumab: A Systematic Review,” published in the May 2025 issue of Annals of Allergy, Asthma & Immunology by Keow et al. 

Dupilumab was used alongside other biologics for individuals unresponsive to monotherapy or managing multiple conditions, though the safety and efficacy of such combinations remained uncertain.  

Researchers conducted a retrospective study to investigate the safety profile, adverse effects (AEs), and clinical outcomes associated with combination biologic therapy.  

They performed a comprehensive search of Ovid Medline, Embase, PubMed, and Web of Science, covering all records up to April 2024. Only English-language primary studies involving individuals treated with dupilumab in combination with at least 1 other biologic agent were considered. Additional relevant studies were discovered through citation chaining and manual screening.  

The results showed that 27 studies, including 156 individuals, were reviewed. Of these, 51.9% received treatment for a single condition, while 48.1% were managed for comorbid conditions. Respiratory disorders (34.7%) and dermatologic disorders (73.3%) were the leading reasons for combination biologic therapy. Mild AEs occurred in 94.9% of cases, most commonly presenting as injection site reactions, upper respiratory infections, and headaches. Serious AEs were infrequent, with none directly linked to the biologic agents. Improved disease control was reported in 62.1% of cases.  

Investigators concluded that the combination of biologic therapy with dupilumab was generally well-tolerated and showed potential benefits for comorbid conditions, treatment-resistant disease, and AEs from monotherapy, though long-term outcomes and condition-specific risks remained uncertain. 

Source: annallergy.org/article/S1081-1206(25)00203-0/abstract